We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Stock Moves 2.74%: What You Should Know
Read MoreHide Full Article
In the latest close session, Boston Scientific (BSX - Free Report) was up +2.74% at $44.92. At the same time, the Dow lost 0.36%, and the tech-heavy Nasdaq gained 0.45%.
The medical device manufacturer's shares have seen a decrease of 10.79% over the last month, not keeping up with the Medical sector's loss of 3.65% and the S&P 500's gain of 1.27%.
Market participants will be closely following the financial results of Boston Scientific in its upcoming release. On that day, Boston Scientific is projected to report earnings of $0.77 per share, which would represent year-over-year growth of 2.67%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.28 billion, up 4.22% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.27 per share and a revenue of $21.29 billion, representing changes of +6.86% and +6.08%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Boston Scientific. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.94% decrease. Boston Scientific is holding a Zacks Rank of #4 (Sell) right now.
In the context of valuation, Boston Scientific is at present trading with a Forward P/E ratio of 13.35. This indicates a discount in contrast to its industry's Forward P/E of 20.16.
Meanwhile, BSX's PEG ratio is currently 1.02. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 1.76 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 98, positioning it in the top 40% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific (BSX) Stock Moves 2.74%: What You Should Know
In the latest close session, Boston Scientific (BSX - Free Report) was up +2.74% at $44.92. At the same time, the Dow lost 0.36%, and the tech-heavy Nasdaq gained 0.45%.
The medical device manufacturer's shares have seen a decrease of 10.79% over the last month, not keeping up with the Medical sector's loss of 3.65% and the S&P 500's gain of 1.27%.
Market participants will be closely following the financial results of Boston Scientific in its upcoming release. On that day, Boston Scientific is projected to report earnings of $0.77 per share, which would represent year-over-year growth of 2.67%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.28 billion, up 4.22% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $3.27 per share and a revenue of $21.29 billion, representing changes of +6.86% and +6.08%, respectively, from the prior year.
Investors should also take note of any recent adjustments to analyst estimates for Boston Scientific. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.94% decrease. Boston Scientific is holding a Zacks Rank of #4 (Sell) right now.
In the context of valuation, Boston Scientific is at present trading with a Forward P/E ratio of 13.35. This indicates a discount in contrast to its industry's Forward P/E of 20.16.
Meanwhile, BSX's PEG ratio is currently 1.02. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. Medical - Products stocks are, on average, holding a PEG ratio of 1.76 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 98, positioning it in the top 40% of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.